$COYA

Coya Therapeutics, Inc. (COYA): Submission of Matters to a Vote of Security Holders

Coya Therapeutics, Inc. (COYA) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. 8-K false 0001835022 0001835022 2026-06-25 2026-06-25 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 25,

Original reporting
Published Jun 25, 2026, 9:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 25, 2026, 9:02 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$COYA
Neutral
high confidence
Mentioned
$COYA
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$COYANeutralLow
01

Why it matters

Stockholders elected two Class I directors (Wilbur Ross, Dieter Weinand) and ratified Weaver and Tidwell, L.L.P. as independent registered public accounting firm for fiscal year ending Dec. 31, 2026.

02

Market read

Routine governance and auditor ratification; no new operating, financial, or regulatory catalyst is disclosed.

03

What to watch

Traders may still check whether any director changes signal strategic shifts, but this 8-K provides only election results, not strategy or performance changes.

Relevance 6/10Novelty 2/10Timing: post-annual-meeting governance update (filed June 25, 2026)

Background

The company submitted results of its June 25, 2026 Annual Meeting under SEC Form 8-K Item 5.07.

Company-level read

Ticker impact

$COYANeutralHigh confidence
Context

Coya Therapeutics filed an 8-K reporting Annual Meeting votes, including election of two Class I directors and auditor ratification for 2026.

Expected impact

Low near-term impact; any reaction is likely muted unless investors were specifically concerned about governance or auditor continuity.

Evidence & confidence

The filing discloses routine shareholder voting outcomes (director election and independent auditor ratification) without new financial guidance, clinical, or regulatory developments.

Market effects

Minimal; governance/auditor ratification does not change sector fundamentals.

Minimal; no cross-border or macro linkage disclosed.

Minimal; filing is company-specific and routine.

Counterpoint

If there had been controversy around auditor choice or director slate, the vote outcome could reduce overhang; however, the filing provides no such context.

Key entities

  • Coya Therapeutics, Inc.

    Nasdaq-listed company reporting Annual Meeting voting results on SEC Form 8-K.

  • Weaver and Tidwell, L.L.P.

    Independent registered public accounting firm ratified for fiscal year ending Dec. 31, 2026.

  • Wilbur Ross

    Elected as Class I director for a three-year term.

  • Dieter Weinand

    Elected as Class I director for a three-year term.

Related articles

$COYAHighAI 8/10

Coya Therapeutics stock reiterated at Buy by H.C. Wainwright on trial enrollment

H.C. Wainwright reiterated a Buy rating on Coya Therapeutics (COYA) with a $18.00 price target, citing full enrollment in its Phase 2/3 ALSTARS trial for ALS treatment. The stock trades at $4.85, suggesting over 270% upside. The trial aims to evaluate COYA 302's efficacy and safety, with top-line data expected in early Q2 2027. The company holds more cash than debt, providing financial flexibility.

$COYAMedAI 8/10

Coya Gains on Test News

Coya Therapeutics (COYA) announced full enrollment of 120 participants in its Phase 2/3 ALSTARS Trial for ALS treatment. Topline data is expected in early Q2 2027. CEO Arun Swaminathan highlighted the milestone and the potential insights from the trial.

$COYALow

Coya Therapeutics, Inc. issued a press release announcing full enrollment of the planned one hundred and twenty (120) patients in the Company’s ongoing Phase…

Coya Therapeutics, Inc. (COYA) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. On October 5, 2026, Coya Therapeutics, Inc. (the “Company”) issued a press release announcing full enrollment of the planned one hundred and twenty (120) patients in the Company’s ongoing Phase 2/3 ALSTARS Trial (NCT07161999) evaluating COYA 302, the Compa

$COYALowAI 8/10

Coya completes enrollment in ALS trial, data due early Q2 2027

Coya Therapeutics (COYA) completed enrollment in its Phase 2/3 ALSTARS trial for ALS treatment COYA 302, with 120 participants. Topline data is expected in early Q2 2027. The trial is a randomized, placebo-controlled study with primary endpoints measuring disease severity. COYA 302 has FDA Fast Track designation. Coya partnered with Dr. Reddy’s for commercialization outside Japan, South America, and Mexico.